Keyphrases
ADAMTS13
100%
Von Willebrand Factor
60%
Sickle Cell Disease
45%
Regadenoson
36%
Metalloprotease
32%
Phase II Trial
27%
Thrombotic Thrombocytopenic Purpura
26%
Vaso-occlusive Crisis
26%
Randomized Phase II Trial
18%
Health-related Quality of Life
18%
Invariant Natural Killer T Cells
18%
Spacer Domain
15%
Thrombospondin Type 1 Repeat
14%
Von Willebrand Factor Cleaving Protease
12%
Vaso-occlusion
11%
Adenosine A2A Receptor Antagonist
10%
Propeptide
10%
Clinical Efficacy
10%
Protease Activity
10%
Glycosylation
10%
Human Plasma
9%
A2A Receptor
9%
Thrombospondin-1 (TSP-1)
9%
Pegcetacoplan
9%
Acknowledgment
9%
Valoctocogene Roxaparvovec
9%
Gene Therapy
9%
Nucleotide Pyrophosphatase
9%
Anti-invariant
9%
INKT Cells
9%
Differentiation Antigen
9%
Peters Plus Syndrome
9%
ER Quality Control
9%
Core Fucosylation
9%
Glycosylation Site
9%
Plasma Cell Differentiation
9%
Heavy Chain
9%
Endothelial Cells
9%
Phosphodiesterase
9%
PC-1
9%
Mouse Plasma
9%
Immunoglobulin M
9%
Paroxysmal Nocturnal Hemoglobinuria
9%
Exosite
9%
Hemophilia
9%
Severe Haemophilia A
9%
Cell Depletion
9%
Invariant NKT Cells
9%
Monoclonal Antibody
9%
Quality Control Mechanism
9%
Biochemistry, Genetics and Molecular Biology
ADAMTS13
81%
Von Willebrand Factor
65%
Metalloproteinase
31%
Metalloendopeptidase
31%
Protease
25%
Thrombotic Thrombocytopenic Purpura
25%
Thrombospondin
20%
Blood Plasma
17%
Secretion (Process)
14%
ADAMTS
14%
Glycosylation
12%
Gene Therapy
9%
Fucosylation
9%
Cathepsin E
9%
Adenosine A2A Receptor
9%
Valoctocogene Roxaparvovec
9%
Receptor Agonists
9%
Subcellular Localization
9%
Cellular Differentiation
9%
Factor XI
9%
Heavy Chain
9%
Haemophilia A
9%
Phosphodiesterase I
9%
Quality Control
9%
Immunoglobulin M
9%
Exosite
9%
Pyrophosphatase
9%
Inorganic Pyrophosphatase
9%
Natural Killer T Cell
9%
Regadenoson
9%
Immunoglobulin Producing Cell
9%
C-Terminus
8%
Oligosaccharide
7%
Fucose
7%
Platelet
6%
Fucosyltransferase
5%
Enzyme
5%
Glucosyltransferase
5%
Disintegrin
5%
Medicine and Dentistry
Sickle-Cell Disease
36%
Von Willebrand Factor Cleaving Proteinase
27%
Regadenoson
27%
Quality of Life
27%
Natural Killer T Cell
18%
Valoctocogene Roxaparvovec
18%
Haemophilia A
18%
Von Willebrand Factor
17%
Infusion
15%
Thrombotic Thrombocytopenic Purpura
15%
Receptor
11%
Patient with Sickle Cell Disease
10%
Gene Therapy
10%
Gene Transfer
9%
Pegcetacoplan
9%
Bismuth Citrate
9%
Monoclonal Antibody
9%
Metalloproteinase
9%
4 Iodo 2,5 Dimethoxyamphetamine
9%
Paroxysmal Nocturnal Hemoglobinuria
9%
Ciclonicate
8%
Drug Megadose
6%
Adverse Event
5%
Clinical Trial
5%
Placebo
5%
